Outputs (802)

In Vivo Evaluation of Pam2Cys‐Modified Cancer‐Testis Antigens as Potential Self‐Adjuvanting Cancer Vaccines (2025)
Journal Article
Aljohani, S., Edmonds, A., Castelletto, V., Seitsonen, J., Hamley, I., Symonds, P., Brentville, V. A., Durrant, L. G., & Mitchell, N. (2025). In Vivo Evaluation of Pam2Cys‐Modified Cancer‐Testis Antigens as Potential Self‐Adjuvanting Cancer Vaccines. Journal of Peptide Science, 31(6), Article e70022. https://doi.org/10.1002/psc.70022

Peptide-based vaccines, formulated with an appropriate adjuvant, offer a versatile platform for targeted cancer immunotherapy. While adjuvants are usually coadministered for nucleic acid and protein vaccines, synthetic peptide antigens afford a more... Read More about In Vivo Evaluation of Pam2Cys‐Modified Cancer‐Testis Antigens as Potential Self‐Adjuvanting Cancer Vaccines.

Pharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage (2025)
Journal Article
Schlosser, A., Pilecki, B., Allen, C., Benest, A. V., Lynch, A. P., Hua, J., Ved, N., Blackley, Z., Andersen, T. L., Hennig, D., Graversen, J. H., Möller, S., Skallerup, S., Ormhøj, M., Lange, C., Agostini, H. T., Grauslund, J., Heegaard, S., Dacheva, I., Koss, M., …Sorensen, G. L. (2025). Pharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage. Molecular Therapy, 33(3), 1048-1072. https://doi.org/10.1016/j.ymthe.2025.01.038

Neovascular age-related macular degeneration and diabetic macular edema are leading causes of vision loss evoked by retinal neovascularization and vascular leakage. The glycoprotein microfibrillar-associated protein 4 (MFAP4) is an integrin αVβ3/5/6... Read More about Pharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage.

SLC1A5 is a key regulator of glutamine metabolism and a prognostic marker for aggressive luminal breast cancer (2025)
Journal Article
Alfarsi, L. H., El Ansari, R., Erkan, B., Fakroun, A., Craze, M. L., Aleskandarany, M. A., Cheng, K. W., Ellis, I. O., Rakha, E. A., & Green, A. R. (2025). SLC1A5 is a key regulator of glutamine metabolism and a prognostic marker for aggressive luminal breast cancer. Scientific Reports, 15(1), Article 2805. https://doi.org/10.1038/s41598-025-87292-1

Cancer cells exhibit altered metabolism, often relying on glutamine (Gln) for growth. Breast cancer (BC) is a heterogeneous disease with varying clinical outcomes. We investigated the role of the amino acid transporter SLC1A5 (ASCT2) and its associat... Read More about SLC1A5 is a key regulator of glutamine metabolism and a prognostic marker for aggressive luminal breast cancer.

High α-SMA expression in the tumor stroma is associated with adverse clinical parameters in mismatch repair–proficient colorectal cancers only (2024)
Journal Article
Sculthorpe, D. J., Denton, A., Fadhil, W., Rusnita, D., Ilyas, M., & Mukherjee, A. (2025). High α-SMA expression in the tumor stroma is associated with adverse clinical parameters in mismatch repair–proficient colorectal cancers only. American Journal of Clinical Pathology, 163(3), 464-472. https://doi.org/10.1093/ajcp/aqae145

Objectives: As mismatch repair status confers differential prognosis in colorectal cancers, this study aimed to determine associations of α–smooth muscle actin (α-SMA) protein expression in mismatch repair–proficient (pMMR) and mismatch repair–defici... Read More about High α-SMA expression in the tumor stroma is associated with adverse clinical parameters in mismatch repair–proficient colorectal cancers only.

Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial. (2024)
Journal Article
Higginson, I. J., Brown, S. T., Oluyase, A. O., May, P., Maddocks, M., Costantini, M., Bajwah, S., Normand, C., Bausewein, C., Simon, S. T., Ryan, K., Currow, D. C., Johnson, M. J., Hart, S. P., Mather, H., Krajnik, M., Tanzi, S., Ghirotto, L., Bolton, C. E., Janowiak, P., …Brown, J. M. (2024). Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial. Lancet Respiratory Medicine, 12(10), 763-774. https://doi.org/10.1016/s2213-2600%2824%2900187-5

Background

Breathlessness frequently becomes severe among people with respiratory disease. Mirtazapine, a widely used antidepressant, has shown promise in the modulation of respiratory sensation and the response to it, as well as reducing feelings... Read More about Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial..

Prognostic and Clinical Significance of the Proliferation Marker MCM7 in Breast Cancer (2024)
Journal Article
Lashen, A. G., Toss, M. S., Rutland, C. S., Green, A. R., Mongan, N. P., & Rakha, E. (2025). Prognostic and Clinical Significance of the Proliferation Marker MCM7 in Breast Cancer. Pathobiology, 92(1), 18-27. https://doi.org/10.1159/000540790

Introduction: Minichromosome maintenance complex component 7 (MCM7) plays an essential role in proliferation and DNA replication of cancer cells. However, the expression and prognostic significance of MCM7 in breast cancer (BC) remain to be defined.... Read More about Prognostic and Clinical Significance of the Proliferation Marker MCM7 in Breast Cancer.

The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study (2024)
Journal Article
Zelenetz, A. D., Jurczak, W., Ribrag, V., Linton, K., Collins, G. P., Jiménez, J. L., Bishton, M., Dholaria, B., Mengarelli, A., Phillips, T. J., Sungala, N., Musuraca, G., Sheehy, O., Van Den Neste, E., Odera, M., Miao, L., Gold, D. P., Ghalie, R. G., & Zinzani, P. L. (2024). The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study. HemaSphere, 8(8), Article e138. https://doi.org/10.1002/hem3.138

In this global phase 2 study in patients with relapsed/refractory follicular lymphoma (FL), zandelisib was administered on intermittent dosing to mitigate immune‐related adverse events and infections that have been reported with oral PI3Kδ inhibitors... Read More about The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.

Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020 (2024)
Journal Article
Liu, H., Stanworth, S. J., McPhail, S., Bishton, M., Rous, B., Bacon, A., & Coats, T. (2024). Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020. Blood Advances, 8(17), 4593-4605. https://doi.org/10.1182/bloodadvances.2024013102

We report 1- and 5-year survival following AML diagnosis and early mortality, within 30 days of systemic anti-cancer therapy (SACT) treatments, using national cancer registry data in England.

Patients aged 18-99 years diagnosed between 2013 and 2... Read More about Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020.

Advantages of automated immunostain analyses for complex membranous immunostains: An exemplar investigating loss of E-cadherin expression in colorectal cancer (2024)
Journal Article
Sculthorpe, D., Denton, A., Rusnita, D., Fadhil, W., Ilyas, M., & Mukherjee, A. (2024). Advantages of automated immunostain analyses for complex membranous immunostains: An exemplar investigating loss of E-cadherin expression in colorectal cancer. Pathology - Research and Practice, 260, Article 155470. https://doi.org/10.1016/j.prp.2024.155470

As pathology moves towards digitisation, biomarker profiling through automated image analysis provides potentially objective and time-efficient means of assessment. This study set out to determine how a complex membranous immunostain, E-cadherin, ass... Read More about Advantages of automated immunostain analyses for complex membranous immunostains: An exemplar investigating loss of E-cadherin expression in colorectal cancer.

A novel and selective fluorescent ligand for the study of adenosine A2B receptors (2024)
Journal Article
Patera, F., Mistry, S. J., Kindon, N. D., Comeo, E., Gouding, J., Kellam, B., Kilpatrick, L. E., Franks, H., & Hill, S. J. (2024). A novel and selective fluorescent ligand for the study of adenosine A2B receptors. Pharmacology Research and Perspectives, 12(4), Article e1223. https://doi.org/10.1002/prp2.1223

Fluorescent ligands have proved to be powerful tools in the study of G protein-coupled receptors in living cells. Here we have characterised a new fluorescent ligand PSB603-BY630 that has high selectivity for the human adenosine A2B receptor (A2BR).... Read More about A novel and selective fluorescent ligand for the study of adenosine A2B receptors.